

BIOLASE, INC  
Form 8-K  
May 12, 2016

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

May 6, 2016

**Biolase, Inc.**

(Exact name of registrant as specified in its charter)

Delaware

000-19627

87-0442441

(State or other jurisdiction  
of incorporation)

(Commission  
File Number)

(I.R.S. Employer  
Identification No.)

4 Cromwell, Irvine, California

92618

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code:

949-361-1200

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Top of the Form**

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

On May 6, 2016, the 2016 Annual Meeting of Stockholders of Biolase, Inc. (the "Company") was held at the Company's headquarters, 4 Cromwell, Irvine, California. The following are the results of the voting on the proposals submitted to stockholders at the Annual Meeting.

1. Stockholders elected all of the Company's five nominees for director to serve a one-year term until the 2017 Annual Meeting of Stockholders and until their respective successors are elected and qualified, as set forth below:

Paul N. Clark  
Votes For: 37,498,038  
Votes Withheld: 248,304  
Broker Non-votes: 13,127,587

Frederic H. Moll  
Votes For: 37,480,545  
Votes Withheld: 265,797  
Broker Non-votes: 13,127,587

Harold C. Flynn, Jr.  
Votes For: 37,503,877  
Votes Withheld: 242,465  
Broker Non-votes: 13,127,587

James R. Talevich  
Votes For: 37,499,114  
Votes Withheld: 247,228  
Broker Non-votes: 13,127,587

Jonathan T. Lord  
Votes For: 37,524,263  
Votes Withheld: 222,079  
Broker Non-votes: 13,127,587

2. Stockholders ratified the selection of BDO USA, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2016, as set forth below:

Votes For: 50,402,647  
Votes Against: 235,137  
Abstentions: 236,145  
Broker Non-votes: 0

3. Stockholders approved the amendment to the 2002 Stock Incentive Plan, as set forth below:

Votes For: 36,197,415  
Votes Against: 1,487,546  
Abstentions: 61,381  
Broker Non-votes: 13,127,587

4. Stockholders voted, on an advisory basis, to approve the compensation of the Company's named executive officers, as set forth below:

Votes For: 36,960,947  
Votes Against: 660,484  
Abstentions: 124,911  
Broker Non-votes: 13,127,587



**Top of the Form**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Biolase, Inc.

*May 12, 2016*

By: *David C. Dreyer*

---

*Name: David C. Dreyer*  
*Title: Chief Financial Officer*